AU2023213106A1 - Therapeutic agent - Google Patents

Therapeutic agent Download PDF

Info

Publication number
AU2023213106A1
AU2023213106A1 AU2023213106A AU2023213106A AU2023213106A1 AU 2023213106 A1 AU2023213106 A1 AU 2023213106A1 AU 2023213106 A AU2023213106 A AU 2023213106A AU 2023213106 A AU2023213106 A AU 2023213106A AU 2023213106 A1 AU2023213106 A1 AU 2023213106A1
Authority
AU
Australia
Prior art keywords
agent
nipd
pyelonephritis
inhibitor
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023213106A
Other languages
English (en)
Inventor
Ines AMBITE
Catharina Svanborg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Selectimmune Pharma AB
Original Assignee
Selectimmune Pharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Selectimmune Pharma AB filed Critical Selectimmune Pharma AB
Publication of AU2023213106A1 publication Critical patent/AU2023213106A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2023213106A 2022-01-28 2023-01-27 Therapeutic agent Pending AU2023213106A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2201139.9 2022-01-28
GBGB2201139.9A GB202201139D0 (en) 2022-01-28 2022-01-28 Therapeutic agent
PCT/EP2023/052076 WO2023144341A1 (en) 2022-01-28 2023-01-27 Therapeutic agent

Publications (1)

Publication Number Publication Date
AU2023213106A1 true AU2023213106A1 (en) 2024-09-12

Family

ID=80621245

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023213106A Pending AU2023213106A1 (en) 2022-01-28 2023-01-27 Therapeutic agent

Country Status (7)

Country Link
US (1) US20250241990A1 (https=)
EP (1) EP4469153A1 (https=)
JP (1) JP2025503251A (https=)
CN (1) CN119156222A (https=)
AU (1) AU2023213106A1 (https=)
GB (1) GB202201139D0 (https=)
WO (1) WO2023144341A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119936405A (zh) * 2025-01-23 2025-05-06 上海市重大传染病和生物安全研究院 血浆IL-1Ra作为生物标志物在儿童脓毒症诊断和预后中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA761627B (en) 1976-03-16 1978-01-25 C Friedmann Improvements in or relating to the treatment of arthritis
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US8153166B2 (en) * 2006-06-08 2012-04-10 Chih-Hsiung Lin Composition for prophylaxis or treatment of urinary system infection and method thereof
GB201617548D0 (en) * 2016-10-17 2016-11-30 Linnane Pharma Ab Novel biological factor

Also Published As

Publication number Publication date
CN119156222A (zh) 2024-12-17
JP2025503251A (ja) 2025-01-30
WO2023144341A1 (en) 2023-08-03
GB202201139D0 (en) 2022-03-16
US20250241990A1 (en) 2025-07-31
EP4469153A1 (en) 2024-12-04

Similar Documents

Publication Publication Date Title
JP5022216B2 (ja) 自己炎症性疾患を処置するためのｉｌ−１アンタゴニストを使用する方法
JP2002220342A (ja) インターロイキン−１媒介疾患および腫瘍壊死因子媒介疾患の治療方法
US8212007B2 (en) Expression and purification of HIP/PAP and uses therefor
JP2014510082A (ja) インターロイキン−１受容体のアンタゴニスト
US20200188471A1 (en) Application of selective tnfr1 antagonist peptide sn10 in preparation of drugs for preventing and treating rheumatoid arthritis
JP6529606B2 (ja) 自己免疫障害及び炎症障害を治療及び／又は予防するための短い合成ペプチド
US20090209468A1 (en) Alpha-neurotoxin proteins with anti-inflammatory properties and uses thereof
CN116323649A (zh) 膜联蛋白a1 n-末端肽的制剂和方法
US20180161393A1 (en) Prg4 for treating gout and its symptoms
US20250241990A1 (en) Therapeutic agent
CN119548617A (zh) 重组xvii型人源化胶原蛋白的新用途
KR20140071272A (ko) 항 당뇨병 펩타이드로서의 아포리포프로테인 ａｉｖ
US12552848B2 (en) Hydrochloride salts of C5a receptor agonist peptides
JP3538616B2 (ja) 間質性肺炎治療薬および当該疾病の動物モデルの作成方法並びにそれを用いるスクリーニング方法
KR20220051418A (ko) 근위축성 측삭 경화증 치료제
JPWO2001080891A1 (ja) 間質性肺炎治療薬および当該疾病の動物モデルの作成方法並びにそれを用いるスクリーニング方法
US11167005B2 (en) Peptides for treating Sjogren's syndrome
JP7813293B2 (ja) コロナウイルス治療法
US20250235506A1 (en) Chimeric il-10/carrier constructs for treatment of pouchitis and methods of use
WO2006063596A2 (en) A composition comprising pp for the treatment of gastrointestinal disorders
JP7384815B2 (ja) 肺の修復に関する方法および組成物
US20230272024A1 (en) Fibroblast growth factor 7 peptide
US7605132B2 (en) Protective factors against inflammation, burns and noxious stimuli
JP2002179588A (ja) チオレドキシンファミリーに属するポリペプチド類を含む炎症予防乃至治療剤
EP4137209A1 (en) Application of tff2 protein and ifn-? protein combination in treatment of a novel coronavirus infection